Crossmark

Dapagliflozin: Improving heart failure outcomes does not necessarily mean increasing costs

Crossref DOI link: https://doi.org/10.1016/j.repc.2024.08.008

Published Print: 2024-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Valentim Gonçalves, António
License Information

Text and Data Mining valid from 2024-12-01

Text and Data Mining valid from 2024-12-01

Version of Record valid from 2024-08-28
More Information

This article is maintained by: Elsevier

Article Title: Dapagliflozin: Improving heart failure outcomes does not necessarily mean increasing costs

Journal Title: Revista Portuguesa de Cardiologia

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.repc.2024.08.008

Content Type: simple-article

Copyright: © 2024 Published by Elsevier España, S.L.U. on behalf of Sociedade Portuguesa de Cardiologia.